Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDuke University
About this trial
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Eligibility criteria
Qualifiers
(CKD Management)
Adults with type 2 diabetes (T2D)
Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
UACR >300 mg/g or
Disqualifiers
(CKD Management)
Type 1 diabetes
Most recent eGFR <20 ml/min/1.73 m2
Prior kidney transplant
Trial design
Treatments tested in this trial
- (IRIS-CKD Management Program): Education
- (IRIS-CKD Management Program): GDMT
Treatment groups
420 Participants
are divided into 2 treatment groupsSponsors and collaborators
Duke University
Lead sponsor
Bayer
Collaborator
Boehringer Ingelheim
Collaborator
Eli Lilly and Company
Collaborator
Source ClinicalTrials.gov